November 4, 2016 09:34 AM EDT

Nestlé invests $145M in Aimmune’s food allergy R&D work, taking the head seat at the deal table

John Carroll

Editor & Founder

Nestlé Health Science is making another big investment in an emerging biotech company. The Brisbane, CA-based Aimmune $AIMT is selling a whopping $145 million stake …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nestlé invests $145M in Aimmune’s food allergy R&D work, taking the head seat at the deal table

John Carroll

Editor & Founder

Sign up to read this article for free.

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Nestlé in­vests $145M in Aim­mune’s food al­ler­gy R&D work, tak­ing the head seat at the deal ta­ble

John Carroll

Editor & Founder

Sign up to read this article for free.

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Nestlé invests $145M in Aimmune’s food allergy R&D work, taking the head seat at the deal table

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks